Among male mice, 69% given gene therapy were alive at 270 days, while controls had a median survival of 197 days.Among male mice, 69% given gene therapy were alive at 270 days, while controls had a median survival of 197 days.
At one year, users had a lower relative rate of major heart and blood vessel events than nonusers, with a hazard ratio of 0.40.At one year, users had a lower relative rate of major heart and blood vessel events than nonusers, with a hazard ratio of 0.40.
At 10 years, users without diabetes had lower dementia risk than multivitamin users (relative risk 0.17) and phentermine users (0.64).At 10 years, users without diabetes had lower dementia risk than multivitamin users (relative risk 0.17) and phentermine users (0.64).
Over a median 15.3 years, heart failure occurred in 20.3% of adults with clustered diagnoses, compared with 6.2% whose obesity was diagnosed first.Over a median 15.3 years, heart failure occurred in 20.3% of adults with clustered diagnoses, compared with 6.2% whose obesity was diagnosed first.
Stroke prevalence was 4.6% among adults with poor sleep quality versus 2.6% among those with excellent sleep quality.Stroke prevalence was 4.6% among adults with poor sleep quality versus 2.6% among those with excellent sleep quality.
Experiments compared mutant and control mice at 2 and 24 months, finding early changes in cells lining brain blood vessels.Experiments compared mutant and control mice at 2 and 24 months, finding early changes in cells lining brain blood vessels.
High scores were associated with 65% lower relative risk of cardiovascular events or cardiovascular death than low scores over 18.7 years.High scores were associated with 65% lower relative risk of cardiovascular events or cardiovascular death than low scores over 18.7 years.
Heart attacks occurred in 3.88% of oral semaglutide users versus 4.31% of injectable users over three years in matched medical-record cohorts.Heart attacks occurred in 3.88% of oral semaglutide users versus 4.31% of injectable users over three years in matched medical-record cohorts.
The definitions disagreed for 17.5% of All of Us participants and 29.1% of UK Biobank participants, with different links to later disease.The definitions disagreed for 17.5% of All of Us participants and 29.1% of UK Biobank participants, with different links to later disease.
Underweight was linked to a higher risk of cardiovascular death, with a hazard ratio—a measure of relative risk—of 1.56 compared with normal weight.Underweight was linked to a higher risk of cardiovascular death, with a hazard ratio—a measure of relative risk—of 1.56 compared with normal weight.
A retrospective comparison of 269 people with one heart failure form, 275 with another and 186 controls found different protein-based aging patterns.A retrospective comparison of 269 people with one heart failure form, 275 with another and 186 controls found different protein-based aging patterns.
The relative rate of death over five years was lower among Hispanic adults than matched non-Hispanic White adults, with a hazard ratio of 0.846.The relative rate of death over five years was lower among Hispanic adults than matched non-Hispanic White adults, with a hazard ratio of 0.846.
Among patients rated low risk, heart attacks and strokes occurred at 8.0-fold and 6.5-fold the rates predicted by two standard calculators.Among patients rated low risk, heart attacks and strokes occurred at 8.0-fold and 6.5-fold the rates predicted by two standard calculators.
For 10-year heart failure prediction, a scan-based model scored 0.84 versus 0.72 for a clinical score in distinguishing future cases from people who remained unaffected.For 10-year heart failure prediction, a scan-based model scored 0.84 versus 0.72 for a clinical score in distinguishing future cases from people who remained unaffected.
An observational analysis of 2,968 CARDIA participants and 4,294 MESA participants linked accumulated burden to unfavorable heart structure and function and higher…An observational analysis of 2,968 CARDIA participants and 4,294 MESA participants linked accumulated burden to unfavorable heart structure and function and higher cardiovascular event risk.
Heart failure flare-ups had a hazard ratio—a relative risk measure—of 0.69 over one year with added drugs versus standard care alone.Heart failure flare-ups had a hazard ratio—a relative risk measure—of 0.69 over one year with added drugs versus standard care alone.
An observational study of adults assessed at average ages 57 and 75 linked two anti-inflammatory blood proteins to later heart failure hospitalizations.An observational study of adults assessed at average ages 57 and 75 linked two anti-inflammatory blood proteins to later heart failure hospitalizations.
Heart failure events or death occurred in 6.1% of oral semaglutide users versus 8.9% of sitagliptin users over one year.Heart failure events or death occurred in 6.1% of oral semaglutide users versus 8.9% of sitagliptin users over one year.
At 60 months, survival was 83.5% among users of glucagon-like peptide-1 receptor agonists, versus 57.4% among matched nonusers.At 60 months, survival was 83.5% among users of glucagon-like peptide-1 receptor agonists, versus 57.4% among matched nonusers.
Among 28,949 UK Biobank participants without cardiovascular disease, genetic analysis linked a fat-carrying particle to 60 proteins associated with artery disease or…Among 28,949 UK Biobank participants without cardiovascular disease, genetic analysis linked a fat-carrying particle to 60 proteins associated with artery disease or heart-valve narrowing.
